Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- URBN +12%, PLCE +6%, MEET +5.4%, (MeetMe reiterates Q3 and FY16 guidance in response to recent volatility in the share price and in anticipation of upcoming investor meetings)
- JKHY +4.5%, AEO +2.9%, HMY +2.3%, ALR +2.1%, CTRN +1%, JASO +0.6%
M&A news: CFNL +3% (follow-up to reports the company is in talks to be acquired by United Bankshares (UBSI))
Select metals/mining stocks trading higher: DRD +2.1%, GG +1.3%, CLF +0.6%, BBL +0.6%, BHP +0.5%, GFI +0.5%
Other news:
Select metals/mining stocks trading higher: DRD +2.1%, GG +1.3%, CLF +0.6%, BBL +0.6%, BHP +0.5%, GFI +0.5%
Other news:
- ANTH +9.4% (appoints William Shanahan, M.D., J.D. as Chief Medical Officer)
- CGIX +9.2% (receives NY State approval for its Focus::Myeloid NGS-based panel for myeloid malignancies including acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms)
- WLDN +6.8% (light volume, Willdan Group receives new three-year $35.4 mln contract by 'leading' utility in the western United States)
- PATK +5.8% (to join S&P SmallCap 600)
- LL +4.8% (announces the final resolution of the Proposition 65 lawsuit originally filed on July 23, 2014)
- SHOP +2.1% (prices offering by co and selling shareholders of 7.5 mln shares of Class A stock at $38.25 per share)
- DY +1.8% ( to join S&P MidCap 400)
- HMC +1.6% (rebound in Nikkei overnight)
Analyst comments:
- SCYX +21.4% (initiated with a Buy at Guggenheim)
- VRX +9.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CTAS +1.9% (upgraded to Overweight from Equal Weight at Barclays)